Venture capital firms that support biotechnology companies are raising billions of dollars to make new investments in 2023, but so far this year VC investors have invested conservatively in drug development, according to first quarter data from Pitchbook and the National Venture Capital Association (NVCA). Perhaps with the most recent new venture funds, the second quarter will reflect a change in the investment strategy.
Finance Watch: Venture Capital Funders Raise Billions For Biotech Investments
Despite New VC Cash, Company Fundraising Sank In Q1
Private Company Edition: Forbion closed two funds totaling €1.35bn ($1.5bn) and Glide Healthcare raised €600m ($657.5m) for its latest fund, joining recent venture capital raises by Lux Capital and Wellington Management, but in the first quarter biopharma VC company financings fell dramatically.
